Latest News

CanalLotus Biotech news and insights

Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment

INDIANAPOLIS, June 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today its partner Junshi Biosciences (HKEX: 1877) has dosed the first healthy volunteer in a study of a potential

Latest News Clinical News 1741
• Read All

Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease

TOKYO, June 8, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced results from the Phase 3 DOLOMITES study, evaluatin

Latest News Clinical News 1858
• Read All

Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 7, 2020 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive Phase 3 results from the ILLUMINATE-A s

Latest News Clinical News 1693
• Read All

Calquence Showed Promising Clinical Improvement in Majority of 19 Hospitalised COVID-19 Patients

June 5, 2020 -- Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcome

Latest News Clinical News 1772
• Read All

The University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of COVID-19 Vaccine Candidate

June 5, 2020, Oslo, Melbourne and Brisbane -- CEPI, the Coalition for Epidemic Preparedness Innovations, CSL (ASX:CSL) and The University of Queensland (UQ) today announced that they have entered into

Latest News Clinical News 1533
• Read All

GSK Announces New Data Presentations from the DREAMM Programme Exploring Investigational Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma

04 June 2020 -- GlaxoSmithKline (GSK) plc today announced new data from its DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical trial programme of belantamab mafodotin in relapsed/r

Latest News Clinical News 1680
• Read All

AstraZeneca Takes Next Steps Towards Broad and Equitable Access to Oxford University’s COVID-19 Vaccine

4 June 2020 -- AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalit

Latest News Clinical News 1520
• Read All

ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis

GENEVA, Switzerland and BOSTON, MA (June 4, 2020) -- ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive he

Latest News Clinical News 1955
• Read All

INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea

SEOUL, South Korea and PLYMOUTH MEETING, Pa., June 4, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnersh

Latest News Clinical News 2026
• Read All

Novavax Awarded Department of Defense Contract for COVID-19 Vaccine

GAITHERSBURG, Md., June 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announc

Latest News Clinical News 1629
• Read All

Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology

NEW YORK--(BUSINESS WIRE) June 03, 2020 -- Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2)

Latest News Clinical News 2017
• Read All

BerGenBio Confirms First Covid-19 Patient Dosed With Bemcentinib in ACCORD Trial

Bergen, Norway - 02 June 2020 -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces

Latest News Clinical News 1861
• Read All
News
Gloved hands holding a globe, global clinical trial drug sourcing
- CanalLotus Biotech -
Int'l Clinical Service Expert

We are the leader
Because of our professionism

WhatsApp Service QR code